

company announcement

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 2 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company's board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Elisabeth Dahl Christensen
2	Reason for the notification	
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	

a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)					
DKK 0.00	75 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	75 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Liselotte Sofie Hyeled
2	Reason for the notification	
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915

b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>1,345 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	1,345 shares		
Price(s)	Volume(s)							
DKK 0.00	1,345 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	1,345 Shares DKK 0.00						
e)	Date of the transaction	2023-02-01						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Liselotte Sofie Hyeled
2	Reason for the notification	
a)	Position/status	Member of the Board of Directors
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)

c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> <tr> <td></td> <td></td> </tr> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares		
Price(s)	Volume(s)							
DKK 0.00	75 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	75 Shares DKK 0.00						
e)	Date of the transaction	2023-02-01						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Mette Bøjer Jensen				
2	Reason for the notification					
a)	Position/status	Member of the Board of Directors				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)					
DKK 0.00	75 shares					

d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	75 Shares DKK 0.00
e)	Date of the transaction	2023-02-01
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Maha Kutay						
2	Reason for the notification							
a)	Position/status	Closely related to Kasim Kutay, member of the Board of Directors						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915						
b)	Nature of the transaction	Purchase of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 964.25</td> <td>434 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 964.25	434 shares		
Price(s)	Volume(s)							
DKK 964.25	434 shares							
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume 	434 Shares						

	• Price	DKK 964.25
e)	Date of the transaction	2023-02-01
f)	Place of the transaction	NASDAQ COPENHAGEN A/S (XCSE)

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Thomas Rantzau				
2	Reason for the notification					
a)	Position/status	Member of the Board of Directors				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)					
DKK 0.00	75 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	75 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated							
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>86,083 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	86,083 shares		
Price(s)	Volume(s)							
DKK 0.00	86,083 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	86,083 Shares DKK 0.00						
e)	Date of the transaction	2023-02-01						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated	
----------	--	--

a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen						
2	Reason for the notification							
a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares		
Price(s)	Volume(s)							
DKK 0.00	75 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	75 Shares DKK 0.00						
e)	Date of the transaction	2023-02-01						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2	Reason for the notification	

a)	Position/status	President and CEO						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 944.76</td> <td>3,396 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 944.76	3,396 shares		
Price(s)	Volume(s)							
DKK 944.76	3,396 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	3,396 Shares DKK 944.76						
e)	Date of the transaction	2023-02-01						
f)	Place of the transaction	AQUIS EXCHANGE EUROPE (AQEU)						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2	Reason for the notification	
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S

b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Sale of shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 942.91</td> <td>13,847 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 942.91	13,847 shares
Price(s)	Volume(s)					
DKK 942.91	13,847 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	13,847 Shares DKK 942.91				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	CBOE EUROPE (BEUP)				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen
2	Reason for the notification	
a)	Position/status	President and CEO
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument,	Shares

	Identification code	Novo Nordisk B DK0060534915						
b)	Nature of the transaction	Sale of shares						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 939.70</td> <td>77 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 939.70	77 shares		
Price(s)	Volume(s)							
DKK 939.70	77 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	77 Shares DKK 939.70						
e)	Date of the transaction	2023-02-01						
f)	Place of the transaction	CBOE EUROPE - DXE DARK ORDER BOOK (NL) (CEUD)						

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen				
2	Reason for the notification					
a)	Position/status	President and CEO				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Sale of shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)		
Price(s)	Volume(s)					

		DKK 944.88	6,449 shares
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	6,449 Shares	DKK 944.88
e)	Date of the transaction	2023-02-01	
f)	Place of the transaction	CBOE EUROPE - DXE ORDER BOOKS (NL) (CEUX)	

1	Details of the person discharging managerial responsibilities/person closely associated						
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen					
2	Reason for the notification						
a)	Position/status	President and CEO					
b)	Initial notification/Amendment	Initial notification					
3	Details of the issuer						
a)	Name	Novo Nordisk A/S					
b)	LEI	549300DAQ1CVT6CXN342					
4	Details of the transaction(s)						
a)	Description of the financial instrument, type of instrument, Identification code	Shares	Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Sale of shares					
c)	Price(s) and volume(s)	<table border="1"> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>DKK 944.03</td> <td>3,503 shares</td> </tr> </table>	Price(s)	Volume(s)	DKK 944.03	3,503 shares	
Price(s)	Volume(s)						
DKK 944.03	3,503 shares						
d)	Aggregated information						

	<ul style="list-style-type: none"> • Aggregated volume • Price 	3,503 Shares DKK 944.03
e)	Date of the transaction	2023-02-01
f)	Place of the transaction	SIGMA X EUROPE AUCTION BOOK (SGMV)

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen				
2	Reason for the notification					
a)	Position/status	President and CEO				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Sale of shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 942.74</td> <td>38 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 942.74	38 shares
Price(s)	Volume(s)					
DKK 942.74	38 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	38 Shares DKK 942.74				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	TURQUOISE EUROPE (TQEX)				

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Lars Fruergaard Jørgensen				
2	Reason for the notification					
a)	Position/status	President and CEO				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Sale of shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 943.23</td> <td>22,690 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 943.23	22,690 shares
Price(s)	Volume(s)					
DKK 943.23	22,690 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	22,690 Shares DKK 943.23				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	NASDAQ COPENHAGEN A/S (XCSE)				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Monique Carter

2	Reason for the notification					
a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>8,963 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	8,963 shares
Price(s)	Volume(s)					
DKK 0.00	8,963 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	8,963 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Monique Carter
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification

3 Details of the issuer					
a)	Name Novo Nordisk A/S				
b)	LEI 549300DAQ1CVT6CXN342				
4 Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s) <table border="1" data-bbox="863 857 1362 1010"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)				
DKK 0.00	75 shares				
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 75 Shares DKK 0.00				
e)	Date of the transaction 2023-02-01				
f)	Place of the transaction Outside a trading venue				

1 Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person Maziar Mike Doustdar
2 Reason for the notification	
a)	Position/status Executive Vice President
b)	Initial notification/Amendment Initial notification
3 Details of the issuer	
a)	Name Novo Nordisk A/S
b)	LEI 549300DAQ1CVT6CXN342

4		Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915							
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)							
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>26,984 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>		Price(s)	Volume(s)	DKK 0.00	26,984 shares		
Price(s)	Volume(s)								
DKK 0.00	26,984 shares								
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	26,984 Shares DKK 0.00							
e)	Date of the transaction	2023-02-01							
f)	Place of the transaction	Outside a trading venue							

1		Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar	
2		Reason for the notification	
a)	Position/status	Executive Vice President	
b)	Initial notification/Amendment	Initial notification	
3		Details of the issuer	
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4		Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument,	Shares	

	Identification code	Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)					
DKK 0.00	75 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	75 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Maziar Mike Doustdar
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915
b)	Nature of the transaction	Sale of shares
c)	Price(s) and volume(s)	

		Price(s)	Volume(s)
		DKK 949.99	1,434 shares
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	1,434 Shares DKK 949.99	
e)	Date of the transaction	2023-02-01	
f)	Place of the transaction	OUTSIDE A TRADING VENUE	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott	
2	Reason for the notification		
a)	Position/status	Executive Vice President	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915	
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	24,286 shares

d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	24,286 Shares DKK 0.00
e)	Date of the transaction	2023-02-01
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott				
2	Reason for the notification					
a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)					
DKK 0.00	75 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume 	75 Shares				

	• Price	DKK 0.00
e)	Date of the transaction	2023-02-01
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Ludovic Helfgott				
2	Reason for the notification					
a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Sale of shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 949.99</td> <td>6,929 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 949.99	6,929 shares
Price(s)	Volume(s)					
DKK 949.99	6,929 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	6,929 Shares DKK 949.99				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	OUTSIDE A TRADING VENUE				

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen				
2	Reason for the notification					
a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>24,286 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	24,286 shares
Price(s)	Volume(s)					
DKK 0.00	24,286 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	24,286 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
----------	--	--

a)	Name of the Board member/Executive/Associated Person	Karsten Munk Knudsen						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares		
Price(s)	Volume(s)							
DKK 0.00	75 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	75 Shares DKK 0.00						
e)	Date of the transaction	2023-02-01						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification	

a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>26,984 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	26,984 shares
Price(s)	Volume(s)					
DKK 0.00	26,984 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	26,984 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	

a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)					
DKK 0.00	75 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	75 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Douglas Langa
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	

a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Sale of shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 949.99</td> <td>13,914 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 949.99	13,914 shares
Price(s)	Volume(s)					
DKK 949.99	13,914 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	13,914 Shares DKK 949.99				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	OUTSIDE A TRADING VENUE				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915
b)	Nature of the transaction	Other transaction (transfer of shares in

		accordance with Long Term Incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>10,978 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	10,978 shares
Price(s)	Volume(s)					
DKK 0.00	10,978 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	10,978 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Martin Holst Lange
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	
a)	Name	Novo Nordisk A/S
b)	LEI	549300DAQ1CVT6CXN342
4	Details of the transaction(s)	
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)
c)	Price(s) and volume(s)	

		Price(s)	Volume(s)
		DKK 0.00	75 shares
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	75 Shares	DKK 0.00
e)	Date of the transaction	2023-02-01	
f)	Place of the transaction	Outside a trading venue	

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler	
2	Reason for the notification		
a)	Position/status	Executive Vice President	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer		
a)	Name	Novo Nordisk A/S	
b)	LEI	549300DAQ1CVT6CXN342	
4	Details of the transaction(s)		
a)	Description of the financial instrument, type of instrument, Identification code	Shares	Novo Nordisk B DK0060534915
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		DKK 0.00	10,978 shares

d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	10,978 Shares DKK 0.00
e)	Date of the transaction	2023-02-01
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler				
2	Reason for the notification					
a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)					
DKK 0.00	75 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume 	75 Shares				

	• Price	DKK 0.00
e)	Date of the transaction	2023-02-01
f)	Place of the transaction	Outside a trading venue

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Marcus Schindler				
2	Reason for the notification					
a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Sale of shares				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 944.96</td> <td>5,000 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 944.96	5,000 shares
Price(s)	Volume(s)					
DKK 944.96	5,000 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	5,000 Shares DKK 944.96				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	NASDAQ COPENHAGEN A/S (XCSE)				

1	Details of the person discharging managerial responsibilities/person closely associated					
a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest				
2	Reason for the notification					
a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>24,286 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	24,286 shares
Price(s)	Volume(s)					
DKK 0.00	24,286 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	24,286 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
----------	--	--

a)	Name of the Board member/Executive/Associated Person	Camilla Sylvest						
2	Reason for the notification							
a)	Position/status	Executive Vice President						
b)	Initial notification/Amendment	Initial notification						
3	Details of the issuer							
a)	Name	Novo Nordisk A/S						
b)	LEI	549300DAQ1CVT6CXN342						
4	Details of the transaction(s)							
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915						
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)						
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares		
Price(s)	Volume(s)							
DKK 0.00	75 shares							
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	75 Shares DKK 0.00						
e)	Date of the transaction	2023-02-01						
f)	Place of the transaction	Outside a trading venue						

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Henrik Ehlers Wulff
2	Reason for the notification	

a)	Position/status	Executive Vice President				
b)	Initial notification/Amendment	Initial notification				
3	Details of the issuer					
a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with Long Term Incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>26,984 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	26,984 shares
Price(s)	Volume(s)					
DKK 0.00	26,984 shares					
d)	Aggregated information <ul style="list-style-type: none"> Aggregated volume Price 	26,984 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name of the Board member/Executive/Associated Person	Henrik Ehlers Wulff
2	Reason for the notification	
a)	Position/status	Executive Vice President
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer	

a)	Name	Novo Nordisk A/S				
b)	LEI	549300DAQ1CVT6CXN342				
4	Details of the transaction(s)					
a)	Description of the financial instrument, type of instrument, Identification code	Shares Novo Nordisk B DK0060534915				
b)	Nature of the transaction	Other transaction (transfer of shares in accordance with restricted stock unit incentive programme)				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>DKK 0.00</td> <td>75 shares</td> </tr> </tbody> </table>	Price(s)	Volume(s)	DKK 0.00	75 shares
Price(s)	Volume(s)					
DKK 0.00	75 shares					
d)	Aggregated information <ul style="list-style-type: none"> • Aggregated volume • Price 	75 Shares DKK 0.00				
e)	Date of the transaction	2023-02-01				
f)	Place of the transaction	Outside a trading venue				

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#) and [YouTube](#).

Contact for further information

Media:

Ambre Brown Morley

+45 3079 9289

abmo@novonordisk.com

Natalia Salomao Abrahao (US)

+1 848 304 1027

niaa@novonordisk.com

Investors:

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com